HIGH

Teva Isotretinoin 30 mg Recall Active for Potency Variations in 10-Count Packs

Teva Pharmaceuticals USA, Inc. recalls 21,984 packages of Isotretinoin Capsules, USP, 30 mg. The lots are distributed to Florida, Ohio, Puerto Rico and Mississippi. The recall is active as of April 15, 2026.

Quick Facts at a Glance

Recall Date
January 12, 2026
Hazard Level
HIGH
Brands
ISOTRETINOIN, Teva Pharmaceuticals USA
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
4 states
At-Risk Groups
GENERAL, PREGNANT

Hazard Information

Superpotent and Subpotent

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Teva Pharmaceuticals USA, Inc or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Isotretinoin capsules are prescribed for severe acne when other treatments fail. The 30 mg dose comes in 10-count prescription packs manufactured for Teva. These are distributed to several states and territories.

Why This Is Dangerous

Potency variations can lead to underdosing or overdosing, impacting safety and efficacy. Serious birth defects risk remains for pregnant patients exposed to isotretinoin.

Industry Context

This recall is not described as part of a broader safety pattern in the provided data.

Real-World Impact

Patients may need physician oversight to adjust dose. No injuries are reported in the data, but potency inconsistency can result in treatment failure or adverse effects.

Practical Guidance

How to identify if yours is affected

  1. Check packaging for NDC 0591-2435-15 (carton) or 0591-2435-45 (blister).
  2. Verify lot numbers: 100055426, 100071518, 100072450.
  3. Note expiration dates: 02/2026, 04/2027, 07/2027.

Where to find product info

Recall notices and lot-specific guidance are on the FDA enforcement page and Teva recall communications.

What timeline to expect

Refunds or replacements guided by Teva recall communications; typically weeks to months depending on pharmacy/provider processing.

If the manufacturer is unresponsive

  • Escalate to the FDA recall contact
  • Consult your healthcare provider for guidance and potential alternatives

How to prevent similar issues

  • Always verify lot numbers before dispensing or consuming isotretinoin.
  • Coordinate with prescriber for dosing adjustments if a potency issue is suspected.
  • Use only isotretinoin from trusted manufacturers with active recalls.

Documentation advice

Keep the recall letter, lot numbers, expiration dates, pharmacy records, and any physician communications for your records.

Product Details

Product: Isotretinoin Capsules, USP, 30 mg, Rx Only, 10 count Prescription Pack. Manufactured for Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054. NDC 0591-2435-15 (carton), NDC 0591-2435-45 (blister). Generic: Isotretinoin. Brand: Isotretinoin. Quantity: 21,984 packages. Distribution: FL, OH, PR, MS. Status: Active recall as of 2026-01-12. Company contact: Teva Pharmaceuticals USA, Inc.

Reported Incidents

No specific injuries or incidents are listed in the provided data. The FDA enforcement page notes classification and distribution details, but does not enumerate injuries.

Key Facts

  • 21,984 packages recalled
  • Lots include 100055426 with exp 02/2026
  • Lots include 100071518 with exp 04/2027
  • Lots include 100072450 with exp 07/2027
  • Distributes to FL, OH, PR, MS

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANT
Injury Types
OTHER

Product Details

Model Numbers
Lots 100055426
Exp. date 02/2026
100071518
Exp. date 04/2027
100072450
+1 more
UPC Codes
0591-2433
0591-2434
0591-2451
+13 more
Affected States
FL, OH, PR, MS
Report Date
April 15, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more